Ask Onix
Unregulated peptides gain popularity on social media
A growing number of individuals are turning to unregulated peptides, injecting themselves with substances labeled "for research purposes only" in hopes of improving skin, muscle recovery, and overall health. Despite warnings from health authorities, influencers and everyday users alike are sharing their experiences online, often downplaying potential risks.
Katie's experience with GHK-Cu
Katie, a mother of two, has been injecting GHK-Cu, a copper peptide, for several weeks. She claims the treatment has nearly erased stretch marks from her pregnancies and improved her skin texture and hair thickness. GHK-Cu, naturally produced by the body, is used topically in skincare but is not approved for injection due to insufficient research on its safety and potential immune reactions.
"I've done a lot of research into them, and I am exercising caution. I started super small just to make sure I didn't notice anything weird."
Katie, peptide user
The science behind peptides
Peptides are short chains of amino acids that act as cellular messengers, influencing skin health, immune function, and hormone regulation. While some peptides, like insulin, have been safely used in medicine for decades, others remain untested in humans. The recent surge in popularity follows the mainstream adoption of GLP-1 weight-loss drugs, which are fully regulated and approved by health authorities.
Unlike GLP-1 medications, many peptides flooding the market exist in a legal gray area. They are not illegal to purchase but are unapproved for human use, bypassing pharmaceutical quality controls. Experts warn that this lack of regulation poses significant risks.
Health risks and expert concerns
Dr. Mike Mrozinski, a general practitioner, describes the trend as a "perfect storm." The success of regulated GLP-1 drugs has normalized self-injection, while social media influencers promote untested peptides as safe and effective. However, these products often lack rigorous human trials, leaving users vulnerable to unknown side effects.
Professor Adam Taylor of Lancaster University has observed adverse reactions among peptide users, including dizziness, diarrhea, rashes, and leg swelling. Long-term risks remain unclear, but recent analyses found that 8% of peptide products may be contaminated with bacterial endotoxins, which can cause fever, fatigue, and even life-threatening conditions like septic shock.
"The people using these products are, in essence, becoming lab rats. There is some data out there, but in pre-clinical models. Essentially, they've been tested on animals, not on humans."
Adam Taylor, Professor of Anatomy, Lancaster University
Jack's story: A gamble on recovery
Jack Sarginson, 24, turned to peptides after a back injury left him in chronic pain. Despite physiotherapy and medical treatment, his condition worsened, impacting his daily life and mental health. In December 2025, he began injecting a peptide cocktail called Wolverine, marketed for its regenerative properties. Within weeks, he reported significant pain relief and no side effects.
"I know there are two sides to this. To some, injecting drugs might seem quite extreme, but since Covid, people are finding ways to take control of their own health. I feel peptides can be beneficial if used responsibly."
Jack Sarginson, peptide user
Dr. Mrozinski cautions that using unregulated peptides is not "bio-hacking" but a "biological gamble." He warns that widespread use could lead to a public health crisis, with chronic conditions emerging from untested substances that traditional medicine may struggle to address.
Clinics and the regulatory gap
Despite the risks, private clinics are increasingly offering peptide therapies. Dr. Syed Omar Babar, an A&E consultant and director of a Leicester clinic, provides treatments using unregulated peptides like BPC-157 and TB-500. He describes this as a "golden era" for peptides, predicting they will play a major role in future healthcare.
However, the lack of human trials and regulatory approval raises questions. Dr. Babar attributes the gap to funding challenges, explaining that developing a peptide from animal studies to a licensed medicine is a costly, years-long process. Many natural peptides are difficult to patent, discouraging pharmaceutical investment.
While Dr. Babar's clinic is overseen by a GMC-registered doctor, the absence of standardized guidelines means treatments rely on clinician experience and peer learning. He emphasizes that patients are fully informed of the risks and that peptides are not presented as treatments for specific conditions.
Regulatory response
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has taken a firm stance against the unregulated peptide market. The agency states it does not tolerate attempts to bypass medicines regulation by selling peptides labeled for "research purposes" when evidence suggests human use. It commits to removing unlicensed products from the market and strongly advises against purchasing or using unauthorized medicinal products, particularly those promoted on social media.
